Would Glioblastoma be the target indication?, page-5

First 5 Last

Share
Profile

Follow
attaman123

154 Posts.

54

04/08/18

04:48

Post #: 34717782
Share

Originally posted by attaman123 ↑

Can Immunotherapy Succeed in Glioblastoma?
May 24, 2018, by NCI Staff

Researchers who study glioblastoma have been hopeful that immunotherapy might be able to succeed where other therapies have not. And in laboratory studies and human clinical trials, they are leaving no immunotherapy stone unturned.

Unfortunately, several immune-based treatments that looked highly promising in early-phase studies of patients with glioblastoma have not panned out in larger, phase 3 clinical trials. But even those failures have a silver lining, said Michael Lim, M.D., who directs the Brain Tumor Immunotherapy program at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center.

...

And then there’s the matter of how the immune system operates in the brain, Dr. Lim said. “We’re understanding now that the immune environment of the brain is very different from other organs,” he explained.

For example, the brain appears to have a different mix of immune cells than other organs (there are many different types of immune cells, each with different responsibilities). For several reasons, Dr. Lim continued, the composition of immune cells in the brain doesn’t readily generate an immune response against tumors the way immune cells in other organs do.

Glioblastoma tumors also seem particularly adept at blunting an immune response. One recently published study, for instance, showed that many of the immune cells in and around glioblastoma tumors tend to be “exhausted”—that is, the molecular machinery the cells need to stimulate their activity is severely impaired.

Below is the link of the full text of the article:
https://www.cancer.gov/news-events/cancer-currents-blog/2018/immunotherapy-glioblastoma

It would still be a long journey for immunotherapy to succeed in glioblastoma because the tumor microenvironment in glioblastoma is immunosuppressive.

Now Patrys' Deoxymab cell-penetrating & BBB-crossing PAT-DX1 antibodies have established a favorable position at the forefront of the growing field of DNA damage response therapeutics, and have demonstrated its ability to significantly enhance survival of animals with MGMT-unmethylated glioblastoma that has a worse prognosis and is more difficult to treat when compared to methylated glioblastoma.

Expand

At present there are three super hot fields for anticancer therapy: Immunotherapy, Antibody-drug conjugate (ADC), PARP inhibitors. Patrys' PAT-DX1 covers both PARPi and ADC, which makes it stand out from the competition and even a potential game changer in the monoclonal antibody therapy field.

PAB Price at posting: 4.2¢ Sentiment: Buy Disclosure: Held
5 Upvote

1 Great analysis

Reply

Top Stories

ASX Market Close: Tariff fatigue truly evident; RBA eftpos proposal sinks Tyro

WIN

'Incorrect datasets': Old irony sets WIN Metals up for golden opportunity at Emjay

PH2

Hydrogen at a crossroads: Plug Power, Pure Hydrogen and Nel ASA between opportunity and crisis – Your profit strategy

AII

Inside the depths of Panasqueira: A legacy carved in rock

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $4.731M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
35	89862129	0.1¢

Sellers (Offers)

Price($)	Vol.	No.
0.2¢	33482941	23

View Market Depth

No.	Vol.	Price($)
35	89862129	0.001
0	0	0.000
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.002	33482941	23
0.003	13757905	10
0.004	700000	1
0.005	624000	3
0.006	300000	1

Last trade - 16.21pm 15/07/2025 (20 minute delay)

PAB (ASX) Chart

Day chart unavailable

Would Glioblastoma be the target indication?, page-5

ASX Market Close: Tariff fatigue truly evident; RBA eftpos proposal sinks Tyro

'Incorrect datasets': Old irony sets WIN Metals up for golden opportunity at Emjay

Hydrogen at a crossroads: Plug Power, Pure Hydrogen and Nel ASA between opportunity and crisis – Your profit strategy

Inside the depths of Panasqueira: A legacy carved in rock

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Would Glioblastoma be the target indication?, page-5

Top Stories

ASX Market Close: Tariff fatigue truly evident; RBA eftpos proposal sinks Tyro

'Incorrect datasets': Old irony sets WIN Metals up for golden opportunity at Emjay

Hydrogen at a crossroads: Plug Power, Pure Hydrogen and Nel ASA between opportunity and crisis – Your profit strategy

Inside the depths of Panasqueira: A legacy carved in rock

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News